Comparative Pharmacology
Head-to-head clinical analysis: NARCAN versus REVEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NARCAN versus REVEX.
NARCAN vs REVEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Opioid receptor antagonist; binds competitively to mu, kappa, and delta opioid receptors, reversing opioid effects.
Nalmefene is an opioid antagonist that competitively binds to mu, delta, and kappa opioid receptors, reversing or preventing opioid effects.
Initial dose: 0.4 mg to 2 mg IV, IM, or SC, repeated every 2 to 3 minutes as needed. For opioid-induced respiratory depression, may use 0.1 to 0.2 mg IV increments in patients with opioid dependence to avoid withdrawal.
0.5 mg to 1 mg intravenous, intramuscular, or subcutaneous, repeated every 2 to 5 minutes as needed, up to a maximum of 2 mg total dose per episode.
None Documented
None Documented
Approximately 1 hour in adults; context: shorter than most opioids (e.g., morphine 2-4 h), necessitating repeated doses for prolonged opioid effects.
Terminal elimination half-life: 2.4-4.2 hours in adults; prolonged in renal impairment (up to 50 hours).
Primarily hepatic metabolism (glucuronidation) followed by renal excretion of metabolites; <5% excreted unchanged in urine.
Renal: 60% as unchanged drug and metabolites; fecal: 40% via biliary elimination.
Category C
Category C
Opioid Antagonist
Opioid Antagonist